Oxotremorine-M is a drug that triggers ataxia, tremor, and spasticity, and is used to study drug efficacy in treatment of Parkinson's disease. Oxotremorine acts as a selective agonist at muscarinic acetylcholine receptors.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, PerkinElmer has been a leading supplier of New Englａnd Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET671:

1. Loke, W.K., Sim, M., Go, M., O-Substituted derivatives of pralidoxime: muscarinic properties and protection against soman effects in rats, European Journal of Pharmacology, Volume 442, Issue 3, 2002, Pages 279-287.
2. Sharif, N.A., Williams, G.W. & DeSantis, L.M. Affinities of muscarinic drugs for [3H]N-methylscopolamine (NMS) and [3H]oxotremorine (OXO) binding to a mixture of M1−M4 muscarinic receptors: Use of NMS/OXO-M ratios to group compounds into potential agonist, partial agonist, and antagonist classes, Neurochem Res, Volume 20, 1995, Pages 669-674.